Tuesday, November 10, 2020

Ambrx Raises $200M More

San Diego-based biopharmaceuticals developer Ambrx has raised $200M in a funding round, according to the company, which included Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management. The company described the round as a "crossover financing", which was managed by BofA Securities. Ambrx is led by CEO and Chairman Dr. Feng Tian. The company has a wide range of programs focused on cancer, the immune system, metabolic, and cariovascular disease. More information »